Figure 2 | Scientific Reports

Figure 2

From: Pharmacological inhibition of cryptochrome and REV-ERB promotes DNA repair and cell cycle arrest in cisplatin-treated human cells

Figure 2

KS15 and SR8278 protect HaCaT and A549 cells against cisplatin treatment. (a) MTT assays were performed in HaCaT cells treated with KS15 and SR8278 (average and SEM, n = 3). (b) HaCaT cells were treated with DMSO or a combination of 50 µM KS15 and 10 µM SR8278 along with the indicated concentrations of cisplatin. MTT assays were performed two days later (average and SEM, n = 3). (c) A549 cells were treated as in (a), and MTT assays were performed (average and SEM, n = 4). (d) MTT assays were performed in A549 cells were treated with cisplatin and DMSO or the combination of 50 µM K15 and 10 µM SR8278 (average and SEM, n = 4).

Back to article page